BOSTON SCIENTIFIC CORP

Cross-vertical regulatory timeline · last 180 days · 86 events

BOSTON SCIENTIFIC CORP is tracked across 4 federal verticals with 86 regulatory events in the last 180 days. Every event below traces to a primary US-government source listed in the References section.

Identifiers

Activity breakdown

Timeline

  1. SEC filing 10-Q — BOSTON SCIENTIFIC CORP — 2026-11-02
  2. SEC filing 8-K — BOSTON SCIENTIFIC CORP — 2026-10-28
  3. Court case cacd Williams v. Boston Scientific Corporation
    28:1332 Diversity-Product Liability
  4. Court case cacd Rogers v. Boston Scientific Corporation
    28:1332 Diversity-Personal Injury
  5. Court case cacd Albright v. Boston Scientific Corporation
    28:1332 Diversity-Product Liability
  6. Court case cacd Bayhi v. Boston Scientific Corporation
    28:1332 Diversity-Product Liability
  7. Court case cacd Lamy v. Boston Scientific Corporation
    28:1332 Diversity-Product Liability
  8. Court case cacd Robinette v. Boston Scientific Corporation
    28:1332 Diversity-Product Liability
  9. Court case txsd James v. Boston Scientific Corporation
    28:1441 Petition for Removal- Personal Injury
  10. Court case cacd Cooper v. Boston Scientific Corporation
    28:1332 Diversity-Product Liability
  11. Clinical trial Boston Scientific Corporation An Optimization Study Evaluating Safety and Efficacy of the Y-90 Glioblastoma (GBM) Device in Patients With Recurrent GBM
    ["Recurrent Glioblastoma"]
  12. SEC filing 8-K — BOSTON SCIENTIFIC CORP — 2026-10-07
  13. Clinical trial Boston Scientific Corporation A Post Approval Study to Evaluate Safety and Effectiveness of Multicompartmental Dosimetry Planning.
    ["Hepatocellular Carcinoma (HCC)"]
  14. Clinical trial Boston Scientific Corporation A Global Randomized Trial Evaluating the FARAFLEX™ Mapping and Pulsed Field Ablation System With Electrographic Flow Mapping in Patients Undergoing Repeat Ablation for Atrial Fibrillation
    ["Atrial Fibrillation (AF)","Persistent Atrial Fibrillation (PersAF)","Paroxysmal Atrial Fibrillation (PAF)"]
  15. Clinical trial Boston Scientific Corporation Impact of Endoscopic Sleeve Gastroplasty (ESG) in Obese Adults With Type 2 Diabetes (T2D)
    ["Type 2 Diabetes Mellitus (T2D)","Obesity (BMI>30)"]
  16. SEC filing 8-K — BOSTON SCIENTIFIC CORP — 2026-09-23
  17. Clinical trial Boston Scientific Corporation Study of Eso-SPONGE for Treating Leaks After Upper Gastrointestinal Surgery
    ["Anastomotic Leaks"]
  18. FDA recall Boston Scientific Corporation Class II
    Device was incorrectly manufactured with a guidewire exit port (referred to in the IFU as the RX port), which is not a design feature associated with this device configuration.
  19. SEC filing 8-K — BOSTON SCIENTIFIC CORP — 2026-09-08
  20. sec.insider.f O'Connor Padraig Andrew EVP, Global Operations $27.4K
  21. Option exercise O'Connor Padraig Andrew EVP, Global Operations
  22. SEC filing 8-K — BOSTON SCIENTIFIC CORP — 2026-08-26
  23. Insider buy Morano Susan E Common Stock $100.4K
  24. FDA recall Boston Scientific Corporation Class I
    Tip may fracture or detach, leading to device fragments remaining within the patient or migrating through the vasculature. Patient impact may include prolonged procedure or life-threatening embolism.
  25. sec.insider.i Woodworth Emily SVP, Global Controller and CAO $150.0K
  26. sec.insider.i Monson Jonathan EVP and CFO $500.0K
  27. FDA recall Boston Scientific Corporation Class II
    There is potential for a delay in AF Burden Alert notification affecting the server software which supports the Insertable Cardiac Monitors (ICMs). Delayed notification of an AF Burden Alert may delay clinical evaluation or therapeutic inte
  28. FDA recall Boston Scientific Corporation Class II
    There is potential for a delay in AF Burden Alert notification affecting the server software which supports the Insertable Cardiac Monitors (ICMs). Delayed notification of an AF Burden Alert may delay clinical evaluation or therapeutic inte
  29. FDA recall Boston Scientific Corporation Class II
    There is potential for a delay in AF Burden Alert notification affecting the server software which supports the Insertable Cardiac Monitors (ICMs). Delayed notification of an AF Burden Alert may delay clinical evaluation or therapeutic inte
  30. Insider buy Habiger David C Common Stock $99.9K
  31. Insider buy Habiger David C Common Stock $6.8K
  32. Insider buy Mahoney Michael F Chairman, President & CEO $9.00M
  33. Insider buy Habiger David C Common Stock $50.1K
  34. SEC filing 10-Q — BOSTON SCIENTIFIC CORP — 2026-08-03
  35. sec.insider.i Mahoney Michael F Chairman, President & CEO $1.07M
  36. Insider buy LUDWIG EDWARD J Common Stock $227.4K
  37. sec.insider.i Fitzgerald Joseph Michael EVP & Group Pres, Cardiology $3.00M
  38. SEC filing 8-K — BOSTON SCIENTIFIC CORP — 2026-07-29
  39. SEC filing 8-K — BOSTON SCIENTIFIC CORP — 2026-07-27
  40. FDA recall Boston Scientific Corporation Class II
    A subset of power adapters used with the connect console may exhibit higher-than-expected resistance in the electrical grounding path. As a result, the power adaptor may fail electrical safety testing during installation.
  41. FDA recall Boston Scientific Corporation Class II
    Device may fail to deploy the cinch implant and/or fail to cut the suture as intended.
  42. FDA recall Boston Scientific Corporation Class II
    Device may fail to deploy the cinch implant and/or fail to cut the suture as intended.
  43. FDA recall Boston Scientific Corporation Class I
    Potential for arterial sheath tip separation or partial tip separation during use.
  44. FDA recall Boston Scientific Corporation Class I
    Potential for arterial sheath tip separation or partial tip separation during use.
  45. sec.insider.f Monson Jonathan EVP and CFO $43.5K
  46. Option exercise Monson Jonathan EVP and CFO
  47. FDA recall Boston Scientific Corporation Class II
    Devices contain recalled Medline Namic Angiographic Control Syringe with Rotating Adaptor. There is a risk of syringe loosening or disconnecting from the manifold, resulting in loose connection or complete disconnection. May lead to difficu
  48. SEC filing 11-K — BOSTON SCIENTIFIC CORP — 2026-06-24
  49. FDA recall Boston Scientific Corporation Class II
    Software anomaly occurs when a user adds one or more vials to the cart and subsequently returns to the Activity Calculator to modify one or more input. When a user modifies an input and selects "Recalculate", the dose calculation is update
  50. FDA recall Boston Scientific Corporation Class II
    Boston Scientific's complaint investigations have identified that a subset of air ingress complaints are associated with hemostatic valve damage related to dilator insertion orientation during device preparation. Valve damage may result in
  51. FDA recall Boston Scientific Corporation Class II
    Boston Scientific is replacing specific FARASTAR PFA generators which have a configuration that is not compatible for use with the FARAPOINT PFA catheter.
  52. FDA recall Boston Scientific Corporation Class II
    Labeling discrepancy: Devices distributed with Instructions For Use (IFU) did not include FARAPOINT PFA catheter information.
  53. FDA recall Boston Scientific Corporation Class II
    Labeling discrepancy: Devices distributed with Instructions For Use (IFU) did not include FARAPOINT PFA catheter information.
  54. FDA recall Boston Scientific Corporation Class II
    Labeling discrepancy: Devices distributed with Instructions For Use (IFU) did not include FARAPOINT PFA catheter information.
  55. FDA recall Boston Scientific Corporation Class II
    Boston Scientific's complaint investigations have identified that a subset of air ingress complaints are associated with hemostatic valve damage related to dilator insertion orientation during device preparation. Valve damage may result in
  56. FDA recall Boston Scientific Corporation Class II
    Boston Scientific's complaint investigations have identified that a subset of air ingress complaints are associated with hemostatic valve damage related to dilator insertion orientation during device preparation. Valve damage may result in
  57. FDA recall Boston Scientific Corporation Class II
    Boston Scientific's complaint investigations have identified that a subset of air ingress complaints are associated with hemostatic valve damage related to dilator insertion orientation during device preparation. Valve damage may result in
  58. sec.insider.g Mahoney Michael F Chairman, President & CEO
  59. FDA recall Boston Scientific Corporation Class II
    Potential sterile breach of the pouches in which devices are packaged.
  60. FDA recall Boston Scientific Corporation Class II
    Potential sterile breach of the pouches in which devices are packaged.
  61. FDA recall Boston Scientific Corporation Class II
    Potential sterile breach of the pouches in which devices are packaged.
  62. FDA recall Boston Scientific Corporation Class II
    Potential sterile breach of the pouches in which devices are packaged.
  63. FDA recall Boston Scientific Corporation Class II
    Potential sterile breach of the pouches in which devices are packaged.
  64. FDA recall Boston Scientific Corporation Class II
    Potential sterile breach of the pouches in which devices are packaged.
  65. FDA recall Boston Scientific Corporation Class II
    Potential sterile breach of the pouches in which devices are packaged.
  66. FDA recall Boston Scientific Corporation Class II
    Potential sterile breach of the pouches in which devices are packaged.
  67. FDA recall Boston Scientific Corporation Class II
    Potential sterile breach of the pouches in which devices are packaged.
  68. FDA recall Boston Scientific Corporation Class II
    Potential sterile breach of the pouches in which devices are packaged.
  69. FDA recall Boston Scientific Corporation Class II
    Potential sterile breach of the pouches in which devices are packaged.
  70. FDA recall Boston Scientific Corporation Class II
    Potential sterile breach of the pouches in which devices are packaged.
  71. SEC filing 4 — Habiger David C — 2026-05-21
  72. SEC filing SD — BOSTON SCIENTIFIC CORP — 2026-05-21
  73. Insider buy LUDWIG EDWARD J Common Stock $202.9K
  74. Insider buy Habiger David C Common Stock $125.8K
  75. Insider buy Pegus Cheryl Common Stock $100.0K
  76. Insider buy Habiger David C Common Stock $125.3K
  77. SEC filing 8-K — BOSTON SCIENTIFIC CORP — 2026-05-18
  78. SEC filing 8-K — BOSTON SCIENTIFIC CORP — 2026-05-18
  79. Clinical trial Boston Scientific Corporation Intracept Minimally-invasive PROcedure for VErtebrogenic Back Pain
    ["Chronic Low-back Pain","Vertebrogenic Pain Syndrome"]
  80. Clinical trial Boston Scientific Corporation SIMPLAAFY Clinical Trial
    ["Atrial Fibrillation","Stroke","Bleeding"]

References

  1. SEC EDGAR filings for BOSTON SCIENTIFIC CORP · Retrieved 2026-11-08 · 33 events in window
  2. ClinicalTrials.gov registry · Retrieved 2026-11-08 · 12 trials
  3. openFDA — recalls, drug labels, adverse events · Retrieved 2026-11-08 · 33 events in window